Cargando…

Risks and burdens of incident dyslipidaemia in long COVID: a cohort study

BACKGROUND: Non-clinical evidence and a few human studies with short follow-ups suggest increased risk of dyslipidaemia in the post-acute phase of COVID-19 (ie, >30 days after SARS-CoV-2 infection). However, detailed large-scale controlled studies with longer follow-ups and in-depth assessment of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Evan, Xie, Yan, Al-Aly, Ziyad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Lancet, Diabetes & Endocrinology 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873268/ https://www.ncbi.nlm.nih.gov/pubmed/36623520 http://dx.doi.org/10.1016/S2213-8587(22)00355-2

Ejemplares similares

Risks and burdens of incident diabetes in long COVID: a cohort study
por: Xie, Yan, et al.
Publicado: (2022)

Risks of mental health outcomes in people with covid-19: cohort study
por: Xie, Yan, et al.
Publicado: (2022)

Long-term gastrointestinal outcomes of COVID-19
por: Xu, Evan, et al.
Publicado: (2023)

Long-term neurologic outcomes of COVID-19
por: Xu, Evan, et al.
Publicado: (2022)

Long-term cardiovascular outcomes of COVID-19
por: Xie, Yan, et al.
Publicado: (2022)

Molnupiravir and risk of post-acute sequelae of covid-19: cohort study
por: Xie, Yan, et al.
Publicado: (2023)

Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status
por: Xie, Yan, et al.
Publicado: (2021)

Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study
por: Xie, Yan, et al.
Publicado: (2020)

Serum phosphorus levels and risk of incident dementia
por: Li, Tingting, et al.
Publicado: (2017)

Risk factors, comorbiditiEs and Atherogenic dysLipidaemia in Indian YOUNG patients with dyslipidaemia attending hospital/clinic: REAL YOUNG (dyslipidaemia) study
por: Iyengar, S. S., et al.
Publicado: (2020)

Long COVID after breakthrough SARS-CoV-2 infection
por: Al-Aly, Ziyad, et al.
Publicado: (2022)

Prevention of long COVID: progress and challenges
por: Al-Aly, Ziyad
Publicado: (2023)

Dyslipidaemia in a Black African diabetic population: burden, pattern and predictors
por: Lumu, William, et al.
Publicado: (2017)

Association of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 Condition
por: Xie, Yan, et al.
Publicado: (2023)

Diabetic dyslipidaemia
por: C. Thambiah, Subashini, et al.
Publicado: (2021)

Burden of Cause-Specific Mortality Associated With PM(2.5) Air Pollution in the United States
por: Bowe, Benjamin, et al.
Publicado: (2019)

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
por: Rizzo, Manfredi, et al.
Publicado: (2011)

Temporal trends of COVID-19 mortality and hospitalisation rates: an observational cohort study from the US Department of Veterans Affairs
por: Cai, Miao, et al.
Publicado: (2021)

Changes in the US Burden of Chronic Kidney Disease From 2002 to 2016: An Analysis of the Global Burden of Disease Study
por: Bowe, Benjamin, et al.
Publicado: (2018)

Association of dyslipidaemia with Alzheimer’s disease in a cohort of postmenopausal women
por: Li, Ning, et al.
Publicado: (2020)

Association of dyslipidaemia with osteoporosis in postmenopausal women
por: Zhang, Lingnan, et al.
Publicado: (2021)

Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans
por: Xie, Yan, et al.
Publicado: (2017)

Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records
por: Xie, Yan, et al.
Publicado: (2023)

Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records
por: Xie, Yan, et al.
Publicado: (2023)

The year in dyslipidaemia 2008 /
Publicado: (2009)

The year in dyslipidaemia 2007
Publicado: (2008)

Treatment of Dyslipidaemia in Children
por: Fiorentino, Riccardo, et al.
Publicado: (2021)

The global and national burden of chronic kidney disease attributable to ambient fine particulate matter air pollution: a modelling study
por: Bowe, Benjamin, et al.
Publicado: (2020)

Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS)
por: Raal, Frederick J, et al.
Publicado: (2013)

Association between dyslipidaemia and the risk of hyperuricaemia: a six-year longitudinal cohort study of elderly individuals in China
por: Xu, Ying, et al.
Publicado: (2022)

Estimates of the 2016 global burden of kidney disease attributable to ambient fine particulate matter air pollution
por: Bowe, Benjamin, et al.
Publicado: (2019)

The interleukin-1 cluster, dyslipidaemia and risk of myocardial infarction
por: Keavney, Bernard
Publicado: (2010)

The year in dyslipidaemia : version en español 2009-2010 /
Publicado: (2010)

Trends in Prevalence of Dyslipidaemias and the Risk of Mortality in Lithuanian Urban Population Aged 45–64 in Relation to the Presence of the Dyslipidaemias and the Other Cardiovascular Risk Factors
por: Luksiene, Dalia, et al.
Publicado: (2014)

Fixed Combination for the Treatment of Dyslipidaemia
por: Ferri, Nicola, et al.
Publicado: (2023)

Ambient fine particulate matter air pollution and the risk of hospitalization among COVID-19 positive individuals: Cohort study
por: Bowe, Benjamin, et al.
Publicado: (2021)

Dyslipidaemia in Rheumatological Autoimmune Diseases
por: Toms, Tracey E, et al.
Publicado: (2011)

The year in dyslipidaemia 2005-2006
Publicado: (2006)

Angina due to hypertension and dyslipidaemia
por: Fox, Kim
Publicado: (2019)

Nutraceuticals in Paediatric Patients with Dyslipidaemia
por: Banderali, Giuseppe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_47o2ausigbvr6lo17gdclm5hnf